AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor

Elena Puccetti, Darja Obradovic, Tim Beissert, Andrea Bianchini, Birgit Washburn, Ferdinando Chiaradonna, Simone Boehrer, Dieter Hoelzer, Oliver Gerhard Ottmann, Pier Giuseppe Pelicci, Clara Nervi, Martin Ruthardt

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML)-associated chromosomal translocations result in formation of chimeric transcription factors, such as PML/RARα, PLZF/RARα, and AML-1/ETO, of which the components are involved in regulation of transcription by chromatin modeling through histone acetylation/deacetylation. The leukemic differentiation block is attributed to deregulated transcription caused by these chimeric fusion proteins, which aberrantly recruit histone-deacetylase (HDAC) activity. One essential differentiation pathway blocked by the leukemic fusion proteins is the vitamin (Vit) D3 signaling. Here we investigated the mechanisms by which the leukemic fusion proteins interfere with VitD3-induced differentiation. The VitD3-receptor (VDR) is, like the retinoid receptors RAR, retinoid X receptor, and the thyroid hormone receptor (TR), a ligand-inducible transcription factor. In the absence of ligand, the transcriptional activity of TR and RAR is silenced by recruitment of HDAC activity through binding to corepressors. In the presence of ligand, TR and RAR activate transcription by releasing HDAC activity and by recruiting histoneacetyltransferase activity. Here we report that VDR binds corepressors in a ligand-dependent manner and that inhibition of HDAC activity increases VitD3 sensitivity of HL-60 cells. Nevertheless, the inhibition of HDAC activity is unable to overcome the block of VitD3-induced differentiation caused by PLZF/RARα expression. Here we demonstrate that the expression of the translocation products PML/RARα and PLZF/RARα impairs the localization of VDR in the nucleus by binding to VDR. Furthermore, the overexpression of VDR in U937 cells expressing AML-related translocation products completely abolishes the block of VltD3-induced differentiation. Taken together these data indicate that the AML-associated translocation products block differentiation not only by interfering with chromatin-modeling but also by sequestering factors Involved in the differentiation signaling pathways, such as VDR in the VitD3-induced differentiation.

Original languageEnglish
Pages (from-to)7050-7058
Number of pages9
JournalCancer Research
Volume62
Issue number23
Publication statusPublished - Dec 1 2002

Fingerprint

Calcitriol Receptors
Histone Deacetylases
Cholecalciferol
Acute Myeloid Leukemia
Thyroid Hormone Receptors
Ligands
Co-Repressor Proteins
Chromatin Assembly and Disassembly
Transcription Factors
Retinoid X Receptors
Genetic Translocation
U937 Cells
Proteins
HL-60 Cells
Retinoids
Acetylation
Histones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Puccetti, E., Obradovic, D., Beissert, T., Bianchini, A., Washburn, B., Chiaradonna, F., ... Ruthardt, M. (2002). AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor. Cancer Research, 62(23), 7050-7058.

AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor. / Puccetti, Elena; Obradovic, Darja; Beissert, Tim; Bianchini, Andrea; Washburn, Birgit; Chiaradonna, Ferdinando; Boehrer, Simone; Hoelzer, Dieter; Ottmann, Oliver Gerhard; Pelicci, Pier Giuseppe; Nervi, Clara; Ruthardt, Martin.

In: Cancer Research, Vol. 62, No. 23, 01.12.2002, p. 7050-7058.

Research output: Contribution to journalArticle

Puccetti, E, Obradovic, D, Beissert, T, Bianchini, A, Washburn, B, Chiaradonna, F, Boehrer, S, Hoelzer, D, Ottmann, OG, Pelicci, PG, Nervi, C & Ruthardt, M 2002, 'AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor', Cancer Research, vol. 62, no. 23, pp. 7050-7058.
Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F et al. AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor. Cancer Research. 2002 Dec 1;62(23):7050-7058.
Puccetti, Elena ; Obradovic, Darja ; Beissert, Tim ; Bianchini, Andrea ; Washburn, Birgit ; Chiaradonna, Ferdinando ; Boehrer, Simone ; Hoelzer, Dieter ; Ottmann, Oliver Gerhard ; Pelicci, Pier Giuseppe ; Nervi, Clara ; Ruthardt, Martin. / AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor. In: Cancer Research. 2002 ; Vol. 62, No. 23. pp. 7050-7058.
@article{e5506ac9e6b24997ab098b728f0a3db8,
title = "AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor",
abstract = "Acute myeloid leukemia (AML)-associated chromosomal translocations result in formation of chimeric transcription factors, such as PML/RARα, PLZF/RARα, and AML-1/ETO, of which the components are involved in regulation of transcription by chromatin modeling through histone acetylation/deacetylation. The leukemic differentiation block is attributed to deregulated transcription caused by these chimeric fusion proteins, which aberrantly recruit histone-deacetylase (HDAC) activity. One essential differentiation pathway blocked by the leukemic fusion proteins is the vitamin (Vit) D3 signaling. Here we investigated the mechanisms by which the leukemic fusion proteins interfere with VitD3-induced differentiation. The VitD3-receptor (VDR) is, like the retinoid receptors RAR, retinoid X receptor, and the thyroid hormone receptor (TR), a ligand-inducible transcription factor. In the absence of ligand, the transcriptional activity of TR and RAR is silenced by recruitment of HDAC activity through binding to corepressors. In the presence of ligand, TR and RAR activate transcription by releasing HDAC activity and by recruiting histoneacetyltransferase activity. Here we report that VDR binds corepressors in a ligand-dependent manner and that inhibition of HDAC activity increases VitD3 sensitivity of HL-60 cells. Nevertheless, the inhibition of HDAC activity is unable to overcome the block of VitD3-induced differentiation caused by PLZF/RARα expression. Here we demonstrate that the expression of the translocation products PML/RARα and PLZF/RARα impairs the localization of VDR in the nucleus by binding to VDR. Furthermore, the overexpression of VDR in U937 cells expressing AML-related translocation products completely abolishes the block of VltD3-induced differentiation. Taken together these data indicate that the AML-associated translocation products block differentiation not only by interfering with chromatin-modeling but also by sequestering factors Involved in the differentiation signaling pathways, such as VDR in the VitD3-induced differentiation.",
author = "Elena Puccetti and Darja Obradovic and Tim Beissert and Andrea Bianchini and Birgit Washburn and Ferdinando Chiaradonna and Simone Boehrer and Dieter Hoelzer and Ottmann, {Oliver Gerhard} and Pelicci, {Pier Giuseppe} and Clara Nervi and Martin Ruthardt",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "62",
pages = "7050--7058",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - AML-associated translocation products block vitamin D3-induced differentiation by sequestering the vitamin D3 receptor

AU - Puccetti, Elena

AU - Obradovic, Darja

AU - Beissert, Tim

AU - Bianchini, Andrea

AU - Washburn, Birgit

AU - Chiaradonna, Ferdinando

AU - Boehrer, Simone

AU - Hoelzer, Dieter

AU - Ottmann, Oliver Gerhard

AU - Pelicci, Pier Giuseppe

AU - Nervi, Clara

AU - Ruthardt, Martin

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Acute myeloid leukemia (AML)-associated chromosomal translocations result in formation of chimeric transcription factors, such as PML/RARα, PLZF/RARα, and AML-1/ETO, of which the components are involved in regulation of transcription by chromatin modeling through histone acetylation/deacetylation. The leukemic differentiation block is attributed to deregulated transcription caused by these chimeric fusion proteins, which aberrantly recruit histone-deacetylase (HDAC) activity. One essential differentiation pathway blocked by the leukemic fusion proteins is the vitamin (Vit) D3 signaling. Here we investigated the mechanisms by which the leukemic fusion proteins interfere with VitD3-induced differentiation. The VitD3-receptor (VDR) is, like the retinoid receptors RAR, retinoid X receptor, and the thyroid hormone receptor (TR), a ligand-inducible transcription factor. In the absence of ligand, the transcriptional activity of TR and RAR is silenced by recruitment of HDAC activity through binding to corepressors. In the presence of ligand, TR and RAR activate transcription by releasing HDAC activity and by recruiting histoneacetyltransferase activity. Here we report that VDR binds corepressors in a ligand-dependent manner and that inhibition of HDAC activity increases VitD3 sensitivity of HL-60 cells. Nevertheless, the inhibition of HDAC activity is unable to overcome the block of VitD3-induced differentiation caused by PLZF/RARα expression. Here we demonstrate that the expression of the translocation products PML/RARα and PLZF/RARα impairs the localization of VDR in the nucleus by binding to VDR. Furthermore, the overexpression of VDR in U937 cells expressing AML-related translocation products completely abolishes the block of VltD3-induced differentiation. Taken together these data indicate that the AML-associated translocation products block differentiation not only by interfering with chromatin-modeling but also by sequestering factors Involved in the differentiation signaling pathways, such as VDR in the VitD3-induced differentiation.

AB - Acute myeloid leukemia (AML)-associated chromosomal translocations result in formation of chimeric transcription factors, such as PML/RARα, PLZF/RARα, and AML-1/ETO, of which the components are involved in regulation of transcription by chromatin modeling through histone acetylation/deacetylation. The leukemic differentiation block is attributed to deregulated transcription caused by these chimeric fusion proteins, which aberrantly recruit histone-deacetylase (HDAC) activity. One essential differentiation pathway blocked by the leukemic fusion proteins is the vitamin (Vit) D3 signaling. Here we investigated the mechanisms by which the leukemic fusion proteins interfere with VitD3-induced differentiation. The VitD3-receptor (VDR) is, like the retinoid receptors RAR, retinoid X receptor, and the thyroid hormone receptor (TR), a ligand-inducible transcription factor. In the absence of ligand, the transcriptional activity of TR and RAR is silenced by recruitment of HDAC activity through binding to corepressors. In the presence of ligand, TR and RAR activate transcription by releasing HDAC activity and by recruiting histoneacetyltransferase activity. Here we report that VDR binds corepressors in a ligand-dependent manner and that inhibition of HDAC activity increases VitD3 sensitivity of HL-60 cells. Nevertheless, the inhibition of HDAC activity is unable to overcome the block of VitD3-induced differentiation caused by PLZF/RARα expression. Here we demonstrate that the expression of the translocation products PML/RARα and PLZF/RARα impairs the localization of VDR in the nucleus by binding to VDR. Furthermore, the overexpression of VDR in U937 cells expressing AML-related translocation products completely abolishes the block of VltD3-induced differentiation. Taken together these data indicate that the AML-associated translocation products block differentiation not only by interfering with chromatin-modeling but also by sequestering factors Involved in the differentiation signaling pathways, such as VDR in the VitD3-induced differentiation.

UR - http://www.scopus.com/inward/record.url?scp=0036895869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036895869&partnerID=8YFLogxK

M3 - Article

C2 - 12460926

AN - SCOPUS:0036895869

VL - 62

SP - 7050

EP - 7058

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 23

ER -